Austrian biotech expects clinical trials for Zika vaccine within a year

Themis Bioscience plans to start clinical trials for its experimental Zika virus vaccine in the next 12 months, according to Reuters.

The Austria-based biotech company is working on the vaccine in conjunction with the Institut Pasteur in France. The research institute holds extensive rights to the new vaccine through a licensing deal with the company.

The Zika vaccine is based on previous technology the biotech used to make a measles vaccine.

Erich Tauber, MD, CEO of Themis Bioscience, says the vaccine's development will benefit from the technology's proven track record for immunizing against measles.

More articles on supply chain:

Medtronic invests $20M in Mazor Robotics
FDA panel endorses Amgen's biosimilar version of Humira
GE stakes claim on cell therapy market with Biosafe acquisition

 

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars